Damora Therapeutics (DMRA) SVP reports 312,535-share stock option grant

Rhea-AI Filing Summary

Damora Therapeutics, Inc. executive Brian Burkavage, SVP of Finance, reported a stock option position on a Form 3. The option gives him the right to buy common stock at $32.00 per share for 312,535 underlying shares, expiring on December 15, 2035.

According to the footnote, 25% of this option will vest on December 15, 2026, with the remainder vesting in equal monthly installments through December 15, 2029, subject to his continued service with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Burkavage Brian

Role SVP, Finance

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 312,535 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Underlying option shares: 312,535 shares Exercise price: $32.00 per share Expiration date: December 15, 2035 +2 more

5 metrics

Underlying option shares 312,535 shares Underlying common stock for reported stock option

Exercise price $32.00 per share Stock option exercise price for common stock

Expiration date December 15, 2035 Option expiration for stock option holding

Initial vesting date December 15, 2026 25% of option vests on this date

Final vesting date December 15, 2029 Remaining option vests in equal monthly installments through this date

Key Terms

Stock Option (right to buy), underlying security, vest, continued service

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

underlying security financial

"underlying_security_title: Common Stock"

vest financial

"This option will vest as to 25% on December 15, 2026"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

continued service financial

"subject to the Reporting Person's continued service to the Issuer"

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Burkavage Brian

(Last) (First) (Middle)

C/O DAMORA THERAPEUTICS, INC.,

221 CRESCENT ST, BUILDING 23, SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/01/2026

3. Issuer Name and Ticker or Trading Symbol
Damora Therapeutics, Inc. [ DMRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	12/15/2035	Common Stock	312,535	$32	D

Explanation of Responses:

1. This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on December 15, 2026 and in equal monthly installments thereafter through December 15, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Garrett Winslow, attorney-in-fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider position did DMRA executive Brian Burkavage report on this Form 3?

Brian Burkavage reported a stock option position giving him rights to buy Damora Therapeutics common shares. The option covers 312,535 underlying shares at a $32.00 exercise price, representing a significant equity-based component of his compensation package.

What are the key terms of Brian Burkavage’s stock option in Damora Therapeutics (DMRA)?

The stock option allows purchase of Damora Therapeutics common stock at $32.00 per share, with 312,535 underlying shares and an expiration date of December 15, 2035. These terms define his long-term potential ownership from this grant.

How does the vesting schedule work for the DMRA stock option reported by Brian Burkavage?

The option vests 25% on December 15, 2026, then in equal monthly installments through December 15, 2029. Vesting is conditioned on his continued service with Damora Therapeutics on each vesting date, tying equity realization to ongoing employment.

Is Brian Burkavage’s stock option in Damora Therapeutics immediately exercisable?

The stock option is not fully exercisable immediately because it vests over time. Only after 25% vests on December 15, 2026, and subsequent monthly vesting through December 15, 2029, will additional portions become exercisable, assuming continued service.

What does the Form 3 filing indicate about derivative holdings for DMRA’s SVP of Finance?

The Form 3 shows a derivative holding: a stock option to acquire 312,535 underlying common shares at $32.00, expiring December 15, 2035. This reflects unexercised options that could convert into shares over time as they vest and are potentially exercised.